Brendan Smith

“Maybe just first on near lab, I was hoping, can you speak a little bit more to what kind of potential cross-selling opportunities you're now seeing in these first 60 days and maybe even broadly, you know, more qualitatively, how conversations with new customers are going now that you've got this, you know, arguably…”

“I guess first, can you actually speak a bit more kind of to the customer breakdown now so far this year? Any kind of particular trends you're seeing with who you're placing new systems with, any visibility into maybe how that evolves or doesn't in the second half?”

“Maybe just kind of a quick follow-up first on exploration. I just want to double-check and make sure that we're thinking about the impact to margins there. Nice to see the revenues coming through.”

“Appreciate all the color on the end market and geographic breakdown in the quarter, especially China and EU. I guess with the biotech funding environment continuing to improve, should we expect growth across end markets to kind of equilibrate a bit?”

“Maybe just another follow-up actually on the filtration commentary a bit. I know you mentioned in your prepared remarks, these were some of the headwinds you had previously acknowledged and were expected.”